港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

巨子生物

80.500

+0.5000.63%

成交量：158.95萬

成交額：1.28億

市值：862.16億

市盈率：35.66

高：81.200

開：79.100

低：79.100

收：80.000

資料載入中...

總覽公司新聞公告

點評 | 鉅子生物：膠原棒勢能超預期，可麗金線上高增拉動環比加速，關注新品迭代＆醫美獲批增量

刘章明消费产业...

資本風雲｜鉅子生物市值登頂，“挑戰”珀萊雅當一哥？

“雙一流”高校迎來“百億”身價副校長！鉅子生物聯合創始人範代娣任高校副校長

範代娣“雙重身份”：西大副校長與百億醫美帝國

每日经济新闻

鉅子生物聯合創始人就任西北大學副校長，範代娣身後站着百億家族

21世纪经济报道

【大行評級｜招銀國際：上調鉅子生物目標價至79.96港元去年業績表現強勁】招銀國際發表研究報告指，鉅子生物去年業績表現強勁，其中收入按年升57%至55億元。該行相信，鉅子生物產品組合成功擴展有助推動其長期快速增長，另外，四種注射產品目前正處於申請階段，並即將商業化。該行將其目標價由69.19港元上調至79.96港元，維持“買入”評級。

招銀國際：升鉅子生物(02367)目標價至79.96港元評級“買入”

業績爆炸增長，鉅子生物卻需要居安思危

远见资本局

【券商聚焦】國證國際維持鉅子生物(02367)“買入”評級指公司多款產品蟬聯榜單TOP1

55.39億！鉅子生物最新年報

《大行》招商證券升鉅子生物(02367.HK)目標價至69元評級“買入”

阿斯达克财经

鉅子生物03月31日主力淨流入2010萬元散戶資金拋售

麥格理：維持鉅子生物“跑贏大市”評級升目標價至86港元

麥格理：維持鉅子生物(02367)“跑贏大市”評級升目標價至86港元

智通财经网

《大行》麥格理：鉅子生物(02367.HK)去年下半年盈利勝市場預期升目標價至86元

阿斯达克财经

鉅子生物盤中漲超4% 獲多家大行調升目標價

港股異動 | 鉅子生物(02367)漲超4% 去年純利同比增長42% 獲多家大行調升目標價

異動解讀 | 鉅子生物發佈強勁年報，股價盤中大漲5.15%

異動解讀 | 鉅子生物業績亮眼，盤中大漲5.15%

鉅子生物2024年年報點評：可復美高增、品類拓展，可麗金調整可期，成長空間廣闊【民生零售|公司點評】

零售新研究

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02367/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02367","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02367\",,,,,undefined,":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":80.5,"timestamp":1746173305030,"preClose":80,"halted":0,"volume":1589493,"delay":0,"floatShares":1071000000,"shares":1071000000,"eps":2.2572501098874693,"marketStatus":"休市中","change":0.5,"latestTime":"05-02 16:08:25","open":79.1,"high":81.2,"low":79.1,"amount":127954799,"amplitude":0.02625,"askPrice":80.5,"askSize":11600,"bidPrice":80.35,"bidSize":800,"shortable":3,"etf":0,"ttmEps":2.2138858680714857,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":7,"adr":0,"listingDate":1667491200000,"exchange":"SEHK","adjPreClose":80,"dividendRate":0.01205,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.2528733909568474,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02367\",,,,,undefined,":{"symbol":"02367","floatShares":1071000000,"roa":"21.92%","roe":"35.88%","lyrEps":2.25725,"volumeRatio":0.2528733909568474,"shares":1071000000,"dividePrice":0.97,"high":81.2,"amplitude":0.02625,"preClose":80,"low":79.1,"week52Low":35,"pbRate":"11.29","psRate":"14.48","week52High":81.8,"institutionHeld":0,"latestPrice":80.5,"committee":-0.870968,"eps":2.2572501098874693,"divideRate":0.01205,"volume":1589493,"delay":0,"ttmEps":2.2138858680714857,"open":79.1,"prevYearClose":49.9,"prevWeekClose":77.1,"prevMonthClose":80,"prevQuarterClose":70.45,"fiveDayClose":77.95,"twentyDayClose":70.45,"sixtyDayClose":56.85},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02367\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525709905","title":"點評 | 鉅子生物：膠原棒勢能超預期，可麗金線上高增拉動環比加速，關注新品迭代＆醫美獲批增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2525709905","media":"刘章明消费产业...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525709905?lang=zh_tw&edition=fundamental","pubTime":"2025-04-06 23:15","pubTimestamp":1743952531,"startTime":"0","endTime":"0","summary":"本文来自方正证券研究所《巨子生物公司点评报告：胶原棒势能超预期，可丽金线上高增拉动环比加速，关注新品迭代＆医美获批增量》，欲了解报告详情，请阅读报告原文。收入拆分：双品牌多渠道高增，25Q1势能延续按品牌：可复美胶原棒势能超预期，焦点稳步拓展放量，可丽金线上驱动增长加速。③可丽金增长超预期，线上高速增长有望拉动整体增长加速。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250407020205a44fdb25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250407020205a44fdb25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","SG9999004311.SGD","BK1207","02367"],"gpt_icon":0},{"id":"2525003794","title":"資本風雲｜鉅子生物市值登頂，“挑戰”珀萊雅當一哥？","url":"https://stock-news.laohu8.com/highlight/detail?id=2525003794","media":"子弹财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525003794?lang=zh_tw&edition=fundamental","pubTime":"2025-04-05 19:00","pubTimestamp":1743850806,"startTime":"0","endTime":"0","summary":"而到了今年，截至4月3日，巨子生物市值已超739亿港元，是珀莱雅的两倍多。随着营收增长，2024年上半年巨子生物净利润达到9.83亿元，超过同期珀莱雅的7.02亿元。截至4月2日，巨子生物市盈率33倍，而珀莱雅则是22倍。净利润比珀莱雅高，估值倍数也比珀莱雅高，综合因素作用下，巨子生物市值超700亿港元，已是珀莱雅的2倍多。根据巨子生物招股书，四款在研产品中前两款预计在2024年第一季度获批取证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250405190642a6b091da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250405190642a6b091da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","SG9999004311.SGD","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2525795228","title":"“雙一流”高校迎來“百億”身價副校長！鉅子生物聯合創始人範代娣任高校副校長","url":"https://stock-news.laohu8.com/highlight/detail?id=2525795228","media":"媒体滚动","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525795228?lang=zh_tw&edition=fundamental","pubTime":"2025-04-05 12:43","pubTimestamp":1743828180,"startTime":"0","endTime":"0","summary":"　　4月3日，陕西省政府官网最新一批人事任免通知显示，从今年4月1日起，任命范代娣为西北大学副校长。　　基于“类人胶原蛋白”科研发明，范代娣与同为西北大学校友的丈夫严建亚创立巨子生物，并在港股上市，截至4月3日收盘，巨子生物总市值为739.64亿港元。　　2024年胡润百富榜中，严建亚、范代娣夫妇以245亿元排在全国第196位，陕西地区富豪第三。　　有消息称，巨子生物成立数年内，范代娣夫妇通过家族信托持股约60%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/y/2025-04-05/doc-inesaxxu3591145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999004311.SGD","02367","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2524203915","title":"範代娣“雙重身份”：西大副校長與百億醫美帝國","url":"https://stock-news.laohu8.com/highlight/detail?id=2524203915","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524203915?lang=zh_tw&edition=fundamental","pubTime":"2025-04-04 19:09","pubTimestamp":1743764940,"startTime":"0","endTime":"0","summary":"西北大学迎来新任副校长。4月3日，陕西省政府官网最新一批人事任免通知显示，从今年4月1日起，任命范代娣为西北大学副校长。基于“类人胶原蛋白”科研发明，范代娣与同为西北大学校友的丈夫严建亚创立巨子生物，并在港股上市，缔造百亿医美帝国。其中，决定从今年4月1日起，任命范代娣为西北大学副校长。2023年7月，范代娣宣布因工作安排辞任巨子生物执行董事职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250404192510972e67be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250404192510972e67be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999004311.SGD","LU2488822045.USD","02367","BK1207"],"gpt_icon":0},{"id":"2524239181","title":"鉅子生物聯合創始人就任西北大學副校長，範代娣身後站着百億家族","url":"https://stock-news.laohu8.com/highlight/detail?id=2524239181","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524239181?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 17:58","pubTimestamp":1743674305,"startTime":"0","endTime":"0","summary":"两年后，她被聘为西北大学副教授。值得一提的是，范代娣与丈夫严建亚同为西北大学校友。据称，范代娣以专利技术入股。很快，范代娣的多个科研成果引发关注。有消息称，巨子生物成立数年内，范代娣夫妇通过家族信托持股约60%。从当时的股权结构来看，巨子生物股权所有者主要为严建亚和范代娣夫妇二人。相关人士指出，按1966年出生计，范代娣如今已59岁。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040318000094cafb8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040318000094cafb8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1207","02367"],"gpt_icon":0},{"id":"2524476946","title":"【大行評級｜招銀國際：上調鉅子生物目標價至79.96港元 去年業績表現強勁】招銀國際發表研究報告指，鉅子生物去年業績表現強勁，其中收入按年升57%至55億元。該行相信，鉅子生物產品組合成功擴展有助推動其長期快速增長，另外，四種注射產品目前正處於申請階段，並即將商業化。該行將其目標價由69.19港元上調至79.96港元，維持“買入”評級。","url":"https://stock-news.laohu8.com/highlight/detail?id=2524476946","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524476946?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 10:19","pubTimestamp":1743646794,"startTime":"0","endTime":"0","summary":"招银国际发表研究报告指，巨子生物去年业绩表现强劲，其中收入按年升57%至55亿元。该行相信，巨子生物产品组合成功扩展有助推动其长期快速增长，另外，四种注射产品目前正处于申请阶段，并即将商业化。该行将其目标价由69.19港元上调至79.96港元，维持“买入”评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/03101949267237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02367"],"gpt_icon":0},{"id":"2524545696","title":"招銀國際：升鉅子生物(02367)目標價至79.96港元 評級“買入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2524545696","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524545696?lang=zh_tw&edition=fundamental","pubTime":"2025-04-02 16:56","pubTimestamp":1743584199,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，巨子生物(02367)去年业绩表现强劲，其中收入同比升57%至55亿元人民币，由于线上收入比例的增加，以及在天猫和抖音上行销成本的上升，公司销售费用比率去年上升3.2个百分点至36.3%。因此，净利润率跌4个百分点至37.2%。该行相信，巨子生物产品组合成功扩展有助推动其长期快速增长，另外，四种注射产品目前正处于申请阶段，并即将商业化。该行将其目标价由69.19港元上调至79.96港元，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1273280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"gpt_icon":0},{"id":"2524107822","title":"業績爆炸增長，鉅子生物卻需要居安思危","url":"https://stock-news.laohu8.com/highlight/detail?id=2524107822","media":"远见资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524107822?lang=zh_tw&edition=fundamental","pubTime":"2025-04-02 09:49","pubTimestamp":1743558541,"startTime":"0","endTime":"0","summary":"然而，业绩高涨的背后，巨子生物潜在的危机也引发了外界的关注。从品牌来看，巨子生物主要依靠可复美拉动业绩，数据显示，2024年可复美实现销售收入45.42亿元，同比增长62.9%，占总营收的比重从上年的79.1%上升至82.0%。事实上，巨子生物所依赖的可复美大单品已经出现了增速下滑的趋势。尽管这一增速依然非常高，但是巨子生物仅依靠这一大单品并不能躺在功劳簿上睡大觉。据了解，巨子生物早期依赖经销商模式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250402111939a6acad52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250402111939a6acad52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1207","02367"],"gpt_icon":0},{"id":"2524177709","title":"【券商聚焦】國證國際維持鉅子生物(02367)“買入”評級 指公司多款產品蟬聯榜單TOP1","url":"https://stock-news.laohu8.com/highlight/detail?id=2524177709","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524177709?lang=zh_tw&edition=fundamental","pubTime":"2025-04-02 09:22","pubTimestamp":1743556927,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国证国际发研报指，巨子生物 2024年实现收入55.4亿元，同比增长57.2%，主要得益于全渠道营销活动的持续加强，胶原棒的稳健增长，以及新品可复美焦点面霜、可丽金胶卷面霜、敷料等成功推出。该行表示，丰富产品系列，多款产品蝉联榜单TOP1。2024年4月上市的可复美焦点面霜，在双十一大促中位列天猫修复面霜热卖榜国货TOP2以及抖音品牌胶原蛋白霜好评榜TOP1。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1956455","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"gpt_icon":0},{"id":"2523914482","title":"55.39億！鉅子生物最新年報","url":"https://stock-news.laohu8.com/highlight/detail?id=2523914482","media":"思宇MedTech","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523914482?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 17:36","pubTimestamp":1743413806,"startTime":"0","endTime":"0","summary":"# 财务数据营业收入：2024年实现收入55.39亿元人民币，同比增长57.2%。归母净利润：归属于母公司持有者的盈利为20.62亿元人民币，同比增长42.1%。其他品牌：2024年收入为1.38亿元人民币，同比增长33.8%，占总收入的2.5%。市场表现巨子生物2024年业绩表现强劲，获得了多家机构的评级上调。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250331182945a6aa7214&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250331182945a6aa7214&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2523913866","title":"《大行》招商證券升鉅子生物(02367.HK)目標價至69元  評級“買入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2523913866","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523913866?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 17:32","pubTimestamp":1743413520,"startTime":"0","endTime":"0","summary":"招商证券发表研究报告指，即使巨子生物(02367.HK) 今年1月已经上调去年下半年业绩指引，其去年下半年销售额及净利润仍较市场预期高出8%及5%，该行认为这势头源于可复美(COMFY)线上销售强劲。展望2025年，管理层预计销售额将录得25%至28%增长。该行指，将集团今年收入预测上调5.6%，并下调2025财年至2026财年营运利润预测，同时将其目标价由60元上调至69元，其评级为“买入”。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20221209170600402_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20221209170600402_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1430476/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06099","02367"],"gpt_icon":0},{"id":"2523992945","title":"鉅子生物03月31日主力淨流入2010萬元 散戶資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2523992945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523992945?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 16:15","pubTimestamp":1743408956,"startTime":"0","endTime":"0","summary":"03月31日, 巨子生物股价涨3.60%，报收70.45元，成交金额4.55亿元，换手率0.63%，振幅5.59%，量比1.42。巨子生物今日主力资金（超大单+大单）净流入2010万元，上一交易日主力净流出547万元。该股近5个交易日上涨2.46%，主力资金累计净流出2346万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入7812万元，其中净流入天数为12日。该股主力净额占比0.03%（主力资金净额/流通市值），港股市场排名200/2651。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250331165619a448550d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250331165619a448550d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","LU2488822045.USD","02367"],"gpt_icon":0},{"id":"2523960895","title":"麥格理：維持鉅子生物“跑贏大市”評級 升目標價至86港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2523960895","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523960895?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 15:56","pubTimestamp":1743407760,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　麦格理发布研报称，巨子生物（02367）去年下半年业绩强劲，盈利同比增长37.5%，符该行预期，并较市场预期高出5%，预计公司增加市场推广开支将可提升品牌知名度并推动新产品销售，并且会以可复美（COMFY）品牌作为进军东南亚市场的重心。麦格理将巨子生物今明两年盈利预测分别下调6.2%及5.4%，主要反映更高的市场推广开支，以及在医疗美容方面的研发成本。麦格理将公司目标价上调18%至86港元，维持“跑赢大市”评级。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：史丽君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-03-31/doc-inerpuqn7092091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02367"],"gpt_icon":0},{"id":"2523966987","title":"麥格理：維持鉅子生物(02367)“跑贏大市”評級 升目標價至86港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2523966987","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523966987?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 14:20","pubTimestamp":1743402038,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，麦格理发布研报称，巨子生物去年下半年业绩强劲，盈利同比增长37.5%，符该行预期，并较市场预期高出5%，预计公司增加市场推广开支将可提升品牌知名度并推动新产品销售，并且会以可复美品牌作为进军东南亚市场的重心。麦格理将巨子生物今明两年盈利预测分别下调6.2%及5.4%，主要反映更高的市场推广开支，以及在医疗美容方面的研发成本。麦格理将公司目标价上调18%至86港元，维持“跑赢大市”评级。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1271448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02367"],"gpt_icon":0},{"id":"2523579299","title":"《大行》麥格理：鉅子生物(02367.HK)去年下半年盈利勝市場預期  升目標價至86元","url":"https://stock-news.laohu8.com/highlight/detail?id=2523579299","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523579299?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 12:33","pubTimestamp":1743395580,"startTime":"0","endTime":"0","summary":"麦格理发表报告，称巨子生物(02367.HK) 去年下半年业绩强劲，盈利按年增长37.5%，符该行预期，并较市场预期高出5%，预计公司增加市场推广开支将可提升品牌知名度并推动新产品销售，并且会以可复美(COMFY)品牌作为进军东南亚市场的重心。麦格理将巨子生物今明两年盈利预测分别下调6.2%及5.4%，主要反映更高的市场推广开支，以及在医疗美容方面的研发成本。麦格理将公司目标价上调18%至86元，维持“跑赢大市”评级。(mn/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 12:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20221209170600934_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20221209170600934_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1430245/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02367"],"gpt_icon":0},{"id":"2523500299","title":"鉅子生物盤中漲超4% 獲多家大行調升目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=2523500299","media":"新浪网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523500299?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 11:48","pubTimestamp":1743392892,"startTime":"0","endTime":"0","summary":"巨子生物盘中涨超4%，截至发稿，股价上涨2.06%，现报69.40港元，成交额2.75亿港元。汇丰研究发表报告指，巨子生物2024年财报表现强劲，符合该行预期。维持“买入”评级，并将目标价由70.6港元升至81.9港元。高盛研报指出，巨子生物去年下半年业务继续超出预期，将其2025至2027财年净利润预测微调不足1%，目前料今年销售及净利润同比增长28%与24%，至71亿及25.5亿元人民币。该行对其目标价由64港元上调至72港元，重申“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025033112111797294a8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025033112111797294a8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367"],"gpt_icon":0},{"id":"2523559569","title":"港股異動 | 鉅子生物(02367)漲超4% 去年純利同比增長42% 獲多家大行調升目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=2523559569","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523559569?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 10:56","pubTimestamp":1743389774,"startTime":"0","endTime":"0","summary":"维持“买入”评级，并将目标价由70.6港元升至81.9港元。高盛研报指出，巨子生物去年下半年业务继续超出预期，将其2025至2027财年净利润预测微调不足1%，目前料今年销售及净利润同比增长28%与24%，至71亿及25.5亿元人民币。该行对其目标价由64港元上调至72港元，重申“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1271361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"gpt_icon":0},{"id":"1188437600","title":"異動解讀 | 鉅子生物發佈強勁年報，股價盤中大漲5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188437600","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188437600?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 10:38","pubTimestamp":1743388711,"startTime":"0","endTime":"0","summary":"周一盘中，巨子生物股价大涨5.15%，引发市场关注。这波涨势很可能源于公司近期发布的2024年度亮眼业绩报告。巨子生物还宣布了可观的派息计划，拟派息12.4亿元，其中包括每股0.602元的末期股息和每股0.592元的特别股息。公司在研发方面的投入也不断加大，2024年研发支出1.1亿元，同比增长42.1%，目前拥有188项在研项目和167项专利。这些因素综合起来，显示出公司强劲的业绩表现和良好的发展前景，很可能是推动股价上涨的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"gpt_icon":0},{"id":"1170995854","title":"異動解讀 | 鉅子生物業績亮眼，盤中大漲5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170995854","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170995854?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 10:38","pubTimestamp":1743388708,"startTime":"0","endTime":"0","summary":"巨子生物今日盘中大涨5.15%，引起市场广泛关注。该股价上涨主要受到公司2024年度优秀业绩的推动。巨子生物近日发布的2024年年度报告显示，公司财务表现强劲，业务发展迅速。值得注意的是，巨子生物旗下两大核心品牌表现出色。可复美品牌收入达45.4亿元，同比增长62.9%；可丽金品牌收入8.4亿元，同比增长36.3%。巨子生物在研发方面也有所突破，2024年研发支出1.1亿元，同比增长42.1%，目前拥有188项在研项目和167项专利。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 巨子生物业绩亮眼，盘中大涨5.15%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"gpt_icon":0},{"id":"2523391165","title":"鉅子生物2024年年報點評：可復美高增、品類拓展，可麗金調整可期，成長空間廣闊【民生零售|公司點評】","url":"https://stock-news.laohu8.com/highlight/detail?id=2523391165","media":"零售新研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523391165?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 10:13","pubTimestamp":1743387231,"startTime":"0","endTime":"0","summary":"24年营收同比+57%，可复美表现亮眼、可丽金未来可期。研究报告信息证券研究报告：《巨子生物2024 年年报点评：可复美高增、品类拓展，可丽金调整可期，成长空间广阔》对外发布时间：2025年03月30日报告撰写:解慧新  执业证号：S0100522100001重要提醒《证券期货投资者适当性管理办法》于2017年7月1日起正式实施，通过本微信订阅号发布的观点和信息仅供民生证券的专业投资者参考，完整的投资观点应以民生证券研究所发布的完整报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250331171436a4485c5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250331171436a4485c5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","LU2488822045.USD","BK1207"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02367\",params:#limit:5,,,undefined,":[{"date":"2025-06-17","symbol":"02367","amount":0.5921,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-06-18","defaultRemindTime":1750123800000,"name":"巨子生物","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-29","payableDate":"2025-06-18","currency":"CNY","dateTimestamp":1750089600000,"payDate":"2025-08-29"},{"date":"2025-03-26","symbol":"02367","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742952600000,"name":null,"time":"盤後","dateTimestamp":1742918400000,"actualEps":null},{"date":"2024-08-19","symbol":"02367","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-06-17","symbol":"02367","amount":0.97,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2024-06-18","defaultRemindTime":1718587800000,"name":"巨子生物","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-05","payableDate":"2024-06-18","currency":"HKD","dateTimestamp":1718553600000,"payDate":"2024-07-05"},{"date":"2024-03-25","symbol":"02367","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02367\",market:\"HK\",,,undefined,":[{"executeDate":"2024-06-17","recordDate":"2024-06-18","paymentDate":"2024-07-05","value":0.97,"currency":"HKD"},{"executeDate":"2025-06-17","recordDate":"2025-06-18","paymentDate":"2025-08-29","value":0.5921,"currency":"CNY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02367\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4737,"buy":0.5263,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5263,"analysts":19,"updateTime":1745424000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02367\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02367","date":"2025-05-02","current":37.455761,"percent":0.891447,"low":18.546195,"twenty":25.86929,"median":29.382648,"eighty":34.212713,"high":60.214956,"avg":30.51844,"sd":6.565878,"marketCap":82402510032},"quantilePoints":[{"date":"2022-11-04","current":28.694216,"twenty":26.512834,"median":26.542085,"eighty":27.833364,"marketCap":25968654960},{"date":"2022-11-11","current":35.577583,"twenty":27.402937,"median":34.819032,"eighty":37.211633,"marketCap":32485133920},{"date":"2022-11-18","current":30.409033,"twenty":29.071802,"median":32.325114,"eighty":36.373143,"marketCap":27670720360},{"date":"2022-11-25","current":29.089974,"twenty":29.309257,"median":30.328688,"eighty":34.970742,"marketCap":26260437600},{"date":"2022-12-02","current":29.440115,"twenty":28.58665,"median":29.786096,"eighty":33.378719,"marketCap":27035200000},{"date":"2022-12-09","current":33.170723,"twenty":28.69893,"median":30.328688,"eighty":33.541593,"marketCap":30744000000},{"date":"2022-12-16","current":33.617702,"twenty":28.859591,"median":31.890871,"eighty":33.525219,"marketCap":31085600000},{"date":"2022-12-23","current":32.235512,"twenty":29.23003,"median":32.061881,"eighty":33.375102,"marketCap":29816800000},{"date":"2022-12-30","current":35.028223,"twenty":29.440115,"median":32.235512,"eighty":33.644993,"marketCap":32793600000},{"date":"2023-01-06","current":34.259259,"twenty":29.598569,"median":32.356077,"eighty":33.906187,"marketCap":32403200000},{"date":"2023-01-13","current":37.514633,"twenty":29.683286,"median":32.593587,"eighty":35.138095,"marketCap":36160800000},{"date":"2023-01-20","current":39.320225,"twenty":29.767789,"median":33.170723,"eighty":36.075015,"marketCap":37576000000},{"date":"2023-01-27","current":41.405428,"twenty":29.847916,"median":33.242723,"eighty":36.22764,"marketCap":39576800000},{"date":"2023-02-03","current":46.017337,"twenty":30.125824,"median":33.502098,"eighty":37.981351,"marketCap":44212800000},{"date":"2023-02-10","current":48.646066,"twenty":30.280481,"median":33.687805,"eighty":39.317619,"marketCap":46457600000},{"date":"2023-02-17","current":47.305048,"twenty":30.475064,"median":33.964048,"eighty":41.148897,"marketCap":44749600000},{"date":"2023-02-24","current":46.898265,"twenty":30.969524,"median":34.88282,"eighty":44.591745,"marketCap":43822400000},{"date":"2023-03-03","current":48.206405,"twenty":31.89643,"median":35.69024,"eighty":46.759698,"marketCap":45335200000},{"date":"2023-03-17","current":60.214956,"twenty":31.932315,"median":36.041848,"eighty":47.552658,"marketCap":56754400000},{"date":"2023-03-24","current":51.699724,"twenty":32.016899,"median":36.568073,"eighty":48.347792,"marketCap":49288000000},{"date":"2023-03-31","current":40.925047,"twenty":32.156582,"median":37.514633,"eighty":48.347792,"marketCap":46848000000},{"date":"2023-04-06","current":40.652856,"twenty":32.21578,"median":38.432644,"eighty":48.279626,"marketCap":46506400000},{"date":"2023-04-14","current":37.246115,"twenty":32.289273,"median":38.307612,"eighty":48.226605,"marketCap":42651200000},{"date":"2023-04-21","current":33.385259,"twenty":32.343692,"median":38.098031,"eighty":47.893759,"marketCap":38210400000},{"date":"2023-04-28","current":30.285025,"twenty":32.289273,"median":37.591448,"eighty":47.642868,"marketCap":34404000000},{"date":"2023-05-05","current":26.161165,"twenty":31.945964,"median":37.33158,"eighty":47.490756,"marketCap":29768000000},{"date":"2023-05-12","current":30.574645,"twenty":30.692284,"median":36.23263,"eighty":47.274687,"marketCap":34550400000},{"date":"2023-05-19","current":31.711515,"twenty":30.746535,"median":35.923479,"eighty":47.115193,"marketCap":35331200000},{"date":"2023-05-25","current":31.182824,"twenty":30.822604,"median":35.69024,"eighty":46.935066,"marketCap":34599200000},{"date":"2023-06-02","current":32.039153,"twenty":30.742861,"median":35.028223,"eighty":46.759698,"marketCap":35428800000},{"date":"2023-06-09","current":32.262222,"twenty":30.684805,"median":34.15987,"eighty":46.167812,"marketCap":35624000000},{"date":"2023-06-16","current":32.772734,"twenty":30.742861,"median":33.693297,"eighty":45.892894,"marketCap":36014400000},{"date":"2023-06-23","current":31.032471,"twenty":30.757557,"median":33.682729,"eighty":45.395124,"marketCap":33916000000},{"date":"2023-06-30","current":31.360803,"twenty":30.757557,"median":33.502098,"eighty":44.617559,"marketCap":33964800000},{"date":"2023-07-07","current":31.376956,"twenty":30.759705,"median":33.358016,"eighty":44.488487,"marketCap":33916000000},{"date":"2023-07-14","current":31.254408,"twenty":30.81937,"median":33.206723,"eighty":42.385946,"marketCap":34257600000},{"date":"2023-07-21","current":29.61115,"twenty":30.759705,"median":32.931722,"eighty":41.535665,"marketCap":32305600000},{"date":"2023-07-28","current":31.165322,"twenty":30.717545,"median":32.723027,"eighty":41.405428,"marketCap":33964800000},{"date":"2023-08-04","current":32.76763,"twenty":30.739187,"median":32.639512,"eighty":41.393979,"marketCap":35770400000},{"date":"2023-08-11","current":32.773868,"twenty":30.757557,"median":32.603384,"eighty":41.176747,"marketCap":35575200000},{"date":"2023-08-18","current":30.610294,"twenty":30.757557,"median":32.513854,"eighty":41.037499,"marketCap":32988800000},{"date":"2023-08-25","current":31.726668,"twenty":30.759705,"median":32.346784,"eighty":40.925047,"marketCap":34208800000},{"date":"2023-09-01","current":27.573424,"twenty":30.671209,"median":32.32831,"eighty":40.652856,"marketCap":36697600000},{"date":"2023-09-08","current":26.75169,"twenty":30.572064,"median":32.277824,"eighty":40.648282,"marketCap":35184800000},{"date":"2023-09-15","current":25.993592,"twenty":30.285025,"median":32.235512,"eighty":40.62978,"marketCap":34452800000},{"date":"2023-09-22","current":25.737943,"twenty":29.809068,"median":32.045764,"eighty":40.128892,"marketCap":33964800000},{"date":"2023-09-29","current":25.066298,"twenty":29.656075,"median":31.997803,"eighty":39.81665,"marketCap":33135200000},{"date":"2023-10-06","current":25.484582,"twenty":29.406098,"median":31.918666,"eighty":39.533705,"marketCap":33672000000},{"date":"2023-10-13","current":24.08012,"twenty":28.952772,"median":31.841433,"eighty":39.348774,"marketCap":31768800000},{"date":"2023-10-20","current":22.598372,"twenty":28.090884,"median":31.767659,"eighty":39.309801,"marketCap":29768000000},{"date":"2023-10-27","current":22.348635,"twenty":27.619397,"median":31.711663,"eighty":39.282609,"marketCap":29426400000},{"date":"2023-11-03","current":25.394448,"twenty":27.541831,"median":31.642548,"eighty":39.168886,"marketCap":33525600000},{"date":"2023-11-10","current":25.843419,"twenty":27.016595,"median":31.492944,"eighty":38.901953,"marketCap":34111200000},{"date":"2023-11-17","current":25.355932,"twenty":26.744612,"median":31.467436,"eighty":38.544946,"marketCap":33769600000},{"date":"2023-11-24","current":25.803053,"twenty":26.578324,"median":31.402883,"eighty":38.289787,"marketCap":34648000000},{"date":"2023-12-01","current":25.805078,"twenty":26.361375,"median":31.373452,"eighty":38.186355,"marketCap":34794400000},{"date":"2023-12-08","current":23.911147,"twenty":26.187226,"median":31.314709,"eighty":38.124793,"marketCap":32110400000},{"date":"2023-12-15","current":23.015122,"twenty":25.978956,"median":31.279712,"eighty":37.928033,"marketCap":31085600000},{"date":"2023-12-22","current":23.970526,"twenty":25.934891,"median":31.256547,"eighty":37.726838,"marketCap":32354400000},{"date":"2023-12-29","current":25.605578,"twenty":25.922833,"median":31.253927,"eighty":37.637537,"marketCap":34745600000},{"date":"2024-01-05","current":24.881987,"twenty":25.805078,"median":31.237017,"eighty":37.514633,"marketCap":33525600000},{"date":"2024-01-12","current":25.701327,"twenty":25.757517,"median":31.165322,"eighty":37.417045,"marketCap":34648000000},{"date":"2024-01-19","current":24.032983,"twenty":25.700075,"median":31.138965,"eighty":37.246115,"marketCap":32354400000},{"date":"2024-01-26","current":24.563567,"twenty":25.531167,"median":31.049171,"eighty":36.903516,"marketCap":32940000000},{"date":"2024-02-02","current":22.773078,"twenty":25.419215,"median":30.993085,"eighty":36.23263,"marketCap":30500000000},{"date":"2024-02-09","current":24.329361,"twenty":25.355932,"median":30.81937,"eighty":36.207681,"marketCap":32744800000},{"date":"2024-02-16","current":25.846624,"twenty":25.369207,"median":30.758631,"eighty":36.108181,"marketCap":34794400000},{"date":"2024-02-23","current":26.457355,"twenty":25.369207,"median":30.717545,"eighty":35.899805,"marketCap":35428800000},{"date":"2024-03-01","current":26.003824,"twenty":25.387892,"median":30.635655,"eighty":35.803782,"marketCap":34843200000},{"date":"2024-03-08","current":26.210688,"twenty":25.395134,"median":30.572064,"eighty":35.667709,"marketCap":35136000000},{"date":"2024-03-15","current":30.241869,"twenty":25.409765,"median":30.44783,"eighty":35.490153,"marketCap":40504000000},{"date":"2024-03-22","current":31.217759,"twenty":25.435494,"median":30.569793,"eighty":35.18968,"marketCap":41772800000},{"date":"2024-03-28","current":26.416103,"twenty":25.461641,"median":30.551779,"eighty":34.970062,"marketCap":41528800000},{"date":"2024-04-05","current":26.713065,"twenty":25.484582,"median":30.44783,"eighty":34.88282,"marketCap":41968000000},{"date":"2024-04-12","current":27.194611,"twenty":25.506915,"median":30.285025,"eighty":34.259259,"marketCap":42748800000},{"date":"2024-04-19","current":29.268508,"twenty":25.516475,"median":30.168532,"eighty":34.060481,"marketCap":45969600000},{"date":"2024-04-26","current":29.89571,"twenty":25.531167,"median":29.89571,"eighty":33.867614,"marketCap":46896800000},{"date":"2024-05-03","current":31.286129,"twenty":25.569811,"median":29.89571,"eighty":33.72816,"marketCap":49044000000},{"date":"2024-05-10","current":35.317002,"twenty":25.600357,"median":30.150227,"eighty":34.911901,"marketCap":51288800000},{"date":"2024-05-17","current":33.551674,"twenty":25.608792,"median":30.245106,"eighty":35.034138,"marketCap":48653600000},{"date":"2024-05-24","current":33.729665,"twenty":25.66112,"median":30.409033,"eighty":35.021714,"marketCap":48800000000},{"date":"2024-05-31","current":34.458991,"twenty":25.697876,"median":30.512617,"eighty":34.936642,"marketCap":49905929000},{"date":"2024-06-07","current":35.513458,"twenty":25.700826,"median":30.572064,"eighty":35.034138,"marketCap":51369298000},{"date":"2024-06-14","current":33.485895,"twenty":25.715973,"median":30.610294,"eighty":35.023883,"marketCap":48392099000},{"date":"2024-06-21","current":32.121521,"twenty":25.745773,"median":30.694377,"eighty":34.964455,"marketCap":46323198000},{"date":"2024-06-28","current":32.099848,"twenty":25.775731,"median":30.739187,"eighty":34.884174,"marketCap":46272737000},{"date":"2024-07-05","current":29.936022,"twenty":25.803458,"median":30.671209,"eighty":34.879736,"marketCap":43144155000},{"date":"2024-07-12","current":29.087996,"twenty":25.812746,"median":30.592469,"eighty":34.858532,"marketCap":41983552000},{"date":"2024-07-19","current":27.898783,"twenty":25.84406,"median":30.569793,"eighty":34.80307,"marketCap":40267878000},{"date":"2024-07-26","current":27.412372,"twenty":25.847354,"median":30.44783,"eighty":34.722361,"marketCap":39712807000},{"date":"2024-08-02","current":26.870727,"twenty":25.853895,"median":30.347362,"eighty":34.692602,"marketCap":38905431000},{"date":"2024-08-09","current":29.53175,"twenty":25.868681,"median":30.263126,"eighty":34.580226,"marketCap":43043233000},{"date":"2024-08-16","current":27.651468,"twenty":25.880225,"median":30.20526,"eighty":34.54918,"marketCap":40318339000},{"date":"2024-08-23","current":20.295155,"twenty":25.847354,"median":30.132576,"eighty":34.503268,"marketCap":39157736000},{"date":"2024-08-30","current":21.43279,"twenty":25.766624,"median":29.936022,"eighty":34.476088,"marketCap":41630325000},{"date":"2024-09-06","current":20.565575,"twenty":25.695677,"median":29.843348,"eighty":34.445054,"marketCap":39965112000},{"date":"2024-09-13","current":18.849184,"twenty":25.540828,"median":29.786096,"eighty":34.363297,"marketCap":36533764000},{"date":"2024-09-20","current":20.082561,"twenty":25.484582,"median":29.694562,"eighty":34.259259,"marketCap":39157736000},{"date":"2024-09-27","current":24.850231,"twenty":25.394448,"median":29.657792,"eighty":34.060481,"marketCap":48745326000},{"date":"2024-10-04","current":29.382648,"twenty":25.395362,"median":29.624666,"eighty":34.023673,"marketCap":57374157000},{"date":"2024-10-10","current":27.207172,"twenty":25.409765,"median":29.557165,"eighty":33.926357,"marketCap":52782206000},{"date":"2024-10-18","current":27.08831,"twenty":25.435494,"median":29.436062,"eighty":33.784845,"marketCap":52277596000},{"date":"2024-10-25","current":27.691447,"twenty":25.469288,"median":29.344363,"eighty":33.707844,"marketCap":53438199000},{"date":"2024-11-01","current":28.012496,"twenty":25.497982,"median":29.274876,"eighty":33.690002,"marketCap":54094192000},{"date":"2024-11-08","current":29.463901,"twenty":25.512651,"median":29.272452,"eighty":33.684759,"marketCap":56465859000},{"date":"2024-11-15","current":26.265769,"twenty":25.52529,"median":29.194481,"eighty":33.660087,"marketCap":49956390000},{"date":"2024-11-22","current":26.278217,"twenty":25.56015,"median":29.088985,"eighty":33.628618,"marketCap":49956390000},{"date":"2024-11-29","current":26.561468,"twenty":25.595136,"median":29.046664,"eighty":33.578085,"marketCap":50461000000},{"date":"2024-12-06","current":27.316407,"twenty":25.595136,"median":28.89327,"eighty":33.512207,"marketCap":51772986000},{"date":"2024-12-13","current":27.527865,"twenty":25.608792,"median":28.855293,"eighty":33.470601,"marketCap":52126213000},{"date":"2024-12-20","current":27.519045,"twenty":25.66112,"median":28.7635,"eighty":33.433798,"marketCap":51823447000},{"date":"2024-12-27","current":26.95045,"twenty":25.695677,"median":28.729978,"eighty":33.410147,"marketCap":50713305000},{"date":"2025-01-03","current":25.718533,"twenty":25.700075,"median":28.694216,"eighty":33.386493,"marketCap":48442560000},{"date":"2025-01-10","current":26.596222,"twenty":25.605578,"median":28.598093,"eighty":33.385259,"marketCap":49905929000},{"date":"2025-01-17","current":28.4557,"twenty":25.610934,"median":28.581538,"eighty":33.383573,"marketCap":53438199000},{"date":"2025-01-24","current":29.058848,"twenty":25.694577,"median":28.62658,"eighty":33.365541,"marketCap":54912816000},{"date":"2025-01-28","current":30.995109,"twenty":25.696776,"median":28.668851,"eighty":33.362531,"marketCap":58878741600},{"date":"2025-02-07","current":31.279146,"twenty":25.700576,"median":28.706002,"eighty":33.347316,"marketCap":59082122400},{"date":"2025-02-14","current":32.46032,"twenty":25.708209,"median":28.7635,"eighty":33.295849,"marketCap":61166775600},{"date":"2025-02-21","current":32.605291,"twenty":25.726297,"median":28.850334,"eighty":33.213923,"marketCap":61776918000},{"date":"2025-02-28","current":33.709306,"twenty":25.745773,"median":28.875802,"eighty":33.347316,"marketCap":63658190400},{"date":"2025-03-07","current":37.167941,"twenty":25.761386,"median":29.014465,"eighty":33.385999,"marketCap":70471447200},{"date":"2025-03-14","current":37.985438,"twenty":25.781535,"median":29.070262,"eighty":33.525362,"marketCap":72047648400},{"date":"2025-03-21","current":37.329923,"twenty":25.803863,"median":29.089974,"eighty":33.667635,"marketCap":70776518400},{"date":"2025-03-28","current":31.329348,"twenty":25.820414,"median":29.153791,"eighty":33.6911,"marketCap":69149472000},{"date":"2025-04-03","current":32.960917,"twenty":25.84406,"median":29.176551,"eighty":33.68679,"marketCap":72606945600},{"date":"2025-04-11","current":32.158951,"twenty":25.847354,"median":29.194481,"eighty":33.675182,"marketCap":70369756800},{"date":"2025-04-17","current":33.426462,"twenty":25.850275,"median":29.270028,"eighty":33.693297,"marketCap":73318778400},{"date":"2025-04-25","current":35.713683,"twenty":25.864757,"median":29.297766,"eighty":33.896985,"marketCap":78403298400},{"date":"2025-05-02","current":37.455761,"twenty":25.86929,"median":29.382648,"eighty":34.212713,"marketCap":82402510032}],"updateTime":1746247968287}}}